# Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

> **NCT03473574** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 128 (actual)

## Conditions studied

- Cholangiocarcinoma
- Gall Bladder Carcinoma
- Cholangiocarcinoma Non-resectable
- Gallbladder Carcinoma Non-Resectable

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT03473574
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-02
- **Primary completion:** 2022-03-15
- **Final completion:** 2022-03-15
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03473574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03473574, "Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03473574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*